Abstract
The organic cation transporter-1 (OCT1) mediates the hepatocellular uptake of cationic drugs and endobiotics from sinusoidal blood. The uptake rates of these compounds may depend on OCT1 expression level. Because little is known about the regulation of the human OCT1 (hOCT1) gene, we characterized the hOCT1 promoter with respect to DNA-response elements and their binding factors. By computer analysis, we identified two adjacent putative DNA-response elements for the liver-enriched homodimeric nuclear receptor hepatocyte nuclear factor-4α (HNF-4α) in the hOCT1 promoter. Each element is of the direct repeat (DR)-2 format, containing directly repeated hexamers separated by two bases. In electrophoretic mobility shift assays, both elements directly interacted with HNF-4α. A luciferase reporter construct containing the hOCT1 promoter was strongly activated by HNF-4α in transiently transfected Huh7 cells. Site-directed mutagenesis of either DR-2 element alone or in combination severely decreased the HNF-4α-mediated activation of the hOCT1 promoter, indicating that both elements are functionally important. Because HNF-4α is a known target for bile acid-mediated suppression of transcription, we studied whether chenodeoxycholic acid (CDCA) suppresses hOCT1 gene expression by inhibiting HNF-4α-mediated transactivation. Treatment of cells with CDCA could indeed suppress the activation of the endogenous hOCT1 gene by HNF-4α. In addition, bile acid-inducible transcriptional repressor, small heterodimer partner (SHP), inhibited activation of the reporter-linked hOCT1 promoter and of the endogenous hOCT1 gene by HNF-4α. In conclusion, the hOCT1 gene, encoding an important drug transporter in the human liver, is activated by HNF-4α and suppressed by bile acids via SHP.
Footnotes
-
This study was supported by Grant PP00B-108511/1 from the Swiss National Science Foundation.
-
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
-
doi:10.1124/jpet.105.099929.
-
ABBREVIATIONS: OCT1/Oct1, organic cation transporter 1; hOCT1, human OCT1; HNF-4α, hepatocyte nuclear factor-4α; GW4064, 3-(2,6-dichlorophenyl)-4-(3′-carboxy-2-chloro-stilben-4-yl)-oxymethyl-5-isopropyl-isoxazole; SHP, small heterodimer partner; PCR, polymerase chain reaction; DR, direct repeat; CDCA, chenodeoxycholic acid; EMSA, electrophoretic mobility shift assay; FXR, farnesoid X receptor; DMSO, dimethyl sulfoxide; WT, wild-type; OAT2, organic anion transporter 2; hOAT2, human OAT2; PPAR, peroxisome proliferator-activated receptor.
- Received December 14, 2005.
- Accepted January 23, 2006.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|